

Contents


PHARMACEUTICAL METHODOLOGY

<i>Table of Contents</i>	VII
<i>Acronyms - Abbreviations</i>	XIII
Introduction	XIV
Preface	XV
Forward	XVI

Book ONE:

Procedures and Methods A to B

Table of Contents – Cumulative TOC for Books No I – 4	1.1
Analytical Validation Procedures – Understanding Analytical Validation	
Analytical Test Method Procedures for HPLC UV and GC made easy	1.2
Handling and working with analytical standards	1.3
IQOQ requirements for laboratory equipment	1.4
Out-of-specification test results	1.5
Ins and Outs of Outliers	1.6
Decision Tree - Out-of-specification Results	1.7
Ruggedness and Robustness	1.8
Post Approval Changes in Testing Sites	1.9
ANDA Impurities in Drug Substances	1.10
Impurities Decision Tree	1.11
Performance Verification of Dissolution Apparatus	1.12
Generic Drug Dissolution and the RLD	1.13
Dissolution Testing of Solid Dosage Forms	1.14
Dissolution Testing of Solid Dosage Forms with BCS	1.15
Biopharmaceutics Classification System	1.16
Bioanalytical Method - Validation of Biostudies	1.17
Acetomenophen and Vitamin C – Assay and Degradation Studies	1.18
Acetomenophen and Vitamin C – Limit Test	1.19
Aciclovir Injection 250mg - Stability Assay and Degradation Studies	
Aciclovir Injection 250mg - Analytical Validation	1.20
Aciclovir Monograph	1.21
Aciclovir 5% CREAM Stability Assay and Degradation Studies	1.22
Aciclovir 5% CREAM Preservative Assay	1.23
Azithromycin Oral Suspension - Stability Assay	1.24
Azithromycin Oral Suspension Monograph	1.25
Azithromycin - Impurities by TLC Stability Studies	1.26
Azithromycin – Reconstituted Uniformity of Content	1.27
Bifonazole Cream 1% Assay and Degradation Products	1.28
Bifonazole Cream 1% - Benzyl Alcohol Assay	1.29
Bisoprolol API Monograph for Release and Stability Studies	



Contents

Book ONE

Procedures and Methods

A to B


	Section
Table of Contents – Cumulative TOC for Books No I – 4	1.1
Bromhexine Assay and IDD Validation	1.30
Bupropion HCl Method Validation – API Chromatographic Purity	1.31
Bupropion HCl Tablets – Uniformity of Content Method Validation	1.32
Bupropion HCl Tablets – Dissolution Method Validation	1.33

Book TWO

Procedures and Methods

C to F

Table of Contents – Cumulative TOC for Books No I – 4	2.1
Captopril Monograph	2.2
Carbamazepine 200mg Tablets - Dissolution Method Validation	2.3
Carbamazepine 400mg ER Tablets Stability Assay/Degradation Products	2.4
Carvedilol 12.5mg Tablets Assay and U of C	2.5
Carvedilol 12.5mg Tablets Dissolution Assay	2.6
Cinnarizine Monograph and Assay	2.7
Cinnarizine Dissolution Assay	2.8
Cinnarizine TLC Assay	2.9
Carbidopa Levodopa Stability Assay and Degradation Studies	2.10
Carbidopa Levodopa ER Stability Assay and Degradation Studies	2.11
Carbidopa Levodopa ER Blend Uniformity	2.12
SMT Tablets and Suspension Assay	2.13
Diclofenac 50 / 75mg EC Stability Assay and Impurity Evaluation	2.14
Enalapril Maleate Tablets Stability Assay and Impurity Evaluation	2.15
Enalapril Maleate Tablets Dissolution	2.16
Erodsteine Capsules - Assay and Related Substance	2.17
Etoolac Tablet – UV Dissolution Validation	2.18
Famotidine - Tablet Assay	2.19
Famotidine - Tablet Stability Assay and Impurity Evaluation	2.20
Famotidine - Assay Validation	2.21
Famotidine - Stability Profile	2.22
Famotidine - Uniformity of Content	2.23
Famotidine - Uniformity of Blend - Validation	2.24
Felodipine ER - Stability Assay and Degradation Studies	2.25
Felodipine ER - Assay	2.26
Felodipine ER - Dissolution and U of C Assay	2.27



Contents

Book TWO


Procedures and Methods C to F

	Section
Fluoxetine Capsules 10 and 20 mg Method Validation of Meta-Fluoxetine	2.8
Fluoxetine Capsules 10 and 20 mg Assay and Meta-Fluoxetine Assay	2.9
Fluoxetine Capsules 10 and 20 mg Dissolution Assay	3.0
Fluoxetine Capsules 10 and 20 mg Dissolution Validation	3.1
Fluconazole Capsules 50 – 200mg Dissolution	3.2
Fluconazole Capsules 50 – 200mg Monograph	3.3
Furosemide 200mg Capsules Stability Assay and Impurity Evaluation	3.4
Furosemide 200mg Capsules Dissolution Assay	3.5

Book THREE

Procedures and Methods G to O

Table of Contents – Cumulative TOC for Books No I – 4	3.1
Gabapentin - 100/200/300/400mg capsules – U of C	3.2
Gabapentin - 100/200/300/400mg capsules - Assay & Stability Evaluation	3.3
Gabapentin - 100/200/300/400mg capsules - Assay & Impurity Evaluation	3.4
Gabapentin - 100/200/300/400mg capsules - Dissolution Assay	3.5
Glipizide ER 10mg - Assay & Impurity Evaluation	3.6
Glipizide ER 10mg - Dissolution Assay	3.7
Glipizide ER 10mg – Cleaning Validation	3.8
Glipizide ER 10mg – Assay for Cleaning Verification	3.9
Glipizide ER 10mg – Uniformity of Content (U of C)	3.10
Ganisetron Ampoules - Assay & Degradation Products/Stability Evaluation	3.11
Ibuprofen 200/400/600mg Tablets - Dissolution Assay for Stability Studies	3.12
Ibuprofen 200/400/600mg Tablets	3.13
Ibuprofen 200/400/600mg API - Assay & Stability Evaluation	3.14
Indomethacin Suppositories - Assay & Stability Evaluation	3.15
Indomethacin CR Capsules - Dissolution Assay	3.16
Indomethacin Suppositories - Assay & Impurity Products/Stability Evaluation	3.17
Isosorbide monohydrate 20mg - Dissolution Assay Method Validation	3.18
Potassium Chloride ER pellets - Monograph	3.19
Ketorolac Tromethamine 10/30mg Injection - Assay & Degradation Studies	3.20
Ketorolac Tromethamine Injection - Monograph	3.21
Levodopa & Benserazide 100/25 & 200/50 API & Related Active Substances	3.22
Levodopa & Benserazide 100/25 & 200/50 – HPLC Assay	3.23
Levodopa & Benserazide 100/25 & 200/50 - Dissolution	3.24
Levodopa & Benserazide 100/25 & 200/50 – TLC Assay	3.25



Contents

Book THREE

G - O

	Section
Table of Contents – Cumulative TOC for Books No 1 - 4	3.1
Levodopa & Benserazide 100/25 & 200/50 – Analytical Validation	3.26
Lisinopril Dihydrate 5/10/20/40mg - Assay & Impurity Evaluation	3.27
Lovastatin 10/20/40mg Tablets - Assay & Degradants for Stability Studies	3.28
Lovastatin 10/20/40mg Tablets - Assay for Stability Studies	3.29
Mesalamine 400mg EC Tablets – Dissolution Test	3.30
Mesalamine 400mg EC API – Mesityl Oxide HPLC Method Validation	3.31
Metformin 500 & 850mg Tablets - Monograph	3.32
Metformin 500 & 850mg Tablets - Assay & Degradants for Stability Studies	3.33
Miconazole Nitrate 2% Cream - Assay	3.34
Miconazole Nitrate 2% Cream - Benzoic Acid HPLC Assay	3.35
Miconazole Nitrate 2% Cream - Assay & Degradants for Stability Studies	3.36
Microbial Limit Test Methods - Validation	3.37
Moclobemide 150/300mg Tablets Assay & Degradants for Stability Studies	3.38
Moclobemide 150/300mg Tablets	3.39
Moclobemide API - ID	3.40
Mupirocin API - Chromatographic Purity	3.41
Mupirocin 2% Ointment - Assay & Impurities for Stability Studies	3.42
Nabumetone 500/750mg Tablets - Assay & Degradants for Stability Studies	3.43
Nabumetone 500/750mg Tablets - Blend U of C	3.44
Nabumetone 500/750mg Tablets - Tablets U of C	3.45
Nefazodone 50/100/150/200/250mg Tablets - Assay	3.46
Nefazodone 50/100/150/200/250mg Tablets – Dissolution Assay	3.47
Nefazodone 50/100/150/200/250mg Tablets – EPT Impurities	3.48
Nefazodone 50/100/150/200/250mg Tablets – U of C	3.49
Ofloxacin 100/200/400mg Tablets - Assay	3.50
Ofloxacin 100/200/400mg Tablets - ID	3.51
Ofloxacin 100/200/400mg Tablets – Impurity Profile	3.52
Ofloxacin 100/200/400mg Tablets – U of C and Dissolution	3.53


Book FOUR

Section

Procedures and Methods

P - Z

Table of Contents – Cumulative TOC for Books No I – 4	4.1
Paclitaxel 30/100mg/mL Injection-Assay Monograph Impurities/Degradants	4.2
Paclitaxel Injection Concentrate - Assay	4.3
Paclitaxel Injection Concentrate – IPQC Assay	4.4
Paclitaxel Injection Concentrate - IPQC Assay for Ethanol	4.5
Paclitaxel Injection Concentrate – ID Release	4.6
Paclitaxel Injection Concentrate – Equipment Cleaning Verification	4.7
Paclitaxel Injection Concentrate – In-Process Control Assay	4.8
Pendil – Assay of PVP K-90	4.9



Contents

Book FOUR

Section

Procedures and Methods

P - Z

Pentoxifylline API - Assay Monograph Impurities/Related Substances	4.10
Pentoxifylline 400mg ER Tablets - Assay Impurities/Degradants/Stability	4.11
Pentoxifylline 400mg ER Tablets – Assay Validation	4.12
Pseudoephedrine HCl & Dexchlorpheniramine – Assay/Impurity for Stability	4.13
Ranitidine 150/300mg Tablets – Chromatographic Purity - TLC	4.14
Sotolol 80/120/160/240mg Caplets – U of C – Analytical Validation	4.15
Sotolol 80/120/160/240mg Caplets – UV Cleaning Verification	4.16
Sotolol 80/120/160/240mg Caplets – Assay Dissolution	4.17
Sotolol 80/120/160/240mg Caplets – Assay Method Validation	4.18
Sparfloxacin 100/200mg – Dissolution Test	4.19
Sparfloxacin 100/200mg - Assay Impurities/Degradants/Stability	4.20
Sulindac 200mg Tablets - Assay Impurities/Degradants/Stability	4.21
Sulindac 200mg Tablets - Dissolution	4.22
Tamoxifen Citrate 10/20/40mg Tablets – Assay Dissolution	4.23
Tamoxifen Citrate 10/20/40mg Tablets - Assay Dissolution Validation	4.24
Tamoxifen Citrate 10/20/40mg Tablets - Assay/Degradants/Stability	4.25
PV Dissolution Apparatus	4.26
Tamoxifen Citrate 10/20/40mg Tablets – Assay Validation (Stressed)	4.27
Terazocin 1/2/5/10mg Tablets - Assay Impurities/Degradants/Stability	4.28
Ticlopidine 250mg Tablets EU – Assay / BHA / Stability Studies	4.29
Ticlopidine 250mg Tablets EU – Assay UV Dissolution	4.30
Ticlopidine 250mg Tablets EU – Assay Monograph Impurities/Degradants	4.31
Ticlopidine 250mg Tablets EU – Prospective Method Validation	4.32
Timolol Ophthalmic 0.25% Solution - Assay Impurities/Degradants/Stability	4.33
Timolol Ophthalmic 0.25/0.5% Solution – Assay BZK preservative	4.34
Timolol Ophthalmic 2.5/5mg/mL Solution – Assay BDB preservative	4.35
Timolol Ophthalmic XE 2.5/5mg/mL Solution - Assay	4.36
Timolol Ophthalmic XE 2.5/5mg/mL Solution – Monograph	4.37
Tramadol 50mg Capsules – Cleaning Verification	4.38
Tramadol 50mg Capsules – Assay Release and Stability	4.39
Tramadol 50mg Capsules – Dissolution Release and Stability	4.40
Tramadol 50mg Capsules – Assay and Impurities	4.41
Verapamil HCl ER Tablets 240mg - Assay Impurities/Degradants/Stability	4.42
Verapamil HCl ER Tablets 240mg - Assay Impurities/Degradants/Stability	4.43
Verapamil HCl ER Tablets 240mg - Assay for Stability Studies	4.44
Verapamil HCl ER Tablets 240mg – U of C / Dissolution and Limit Test	4.45
Verapamil HCl ER 5mg/2mL Injection - Assay Impurities/Degradants/Stability	4.46
1 α Hydroxycholecalciferol Drops 0.25mcg - Assay for Stability studies	4.47
Ziac (Bisoprolol+HCT) Tablets - Assay IDD / Impurities/Degradants	4.48
Ziac (Bisoprolol+HCT) Tablets – UV Dissolution Assay	4.49
Ziac (Bisoprolol 2.5/5/10mg +HCT 6.25mg) Granulate – U of C Blend	4.50

ISSN 0793 8756 – Print Version
 AN ON-GOING SERIES
Additional volumes in preparation
 ISBN 0793 8640 - Electronic Version
 Handbook Development 24 Volume Series
 ISSN 24 Volume Series Number 0793 7792 - Electronic Version

EDITORIAL PREFACE

Handbook of Generic Development - Oral Capsule Dosage Form

This handbook represents the **new** International Edition of the ongoing **24** volume *series* of Generic Drug Development and appears under the cumulative title of the Handbook *series* of Generic Drug Development. The ongoing series is updated annually at the end of each year.

This is an ongoing process as new data, specifications and process techniques are added on a continual and expanding basis. This handbook is fact, never fully complete, as each new annual edition brings an enlarged and extended profile in the drug development process, as well as new agency rules, guidelines and guidance to industry which continues to be added year by year as the global product data base expands.


Currently over 150 scientific publications and drug development conferences are annually referenced in the **24** volume Handbook *series* of Generic Drug Development.

This mammoth task presents a continual ongoing commitment by the scientific review committee to the improvement of the technical databases and the product specific drug development requirements and know-how technology accessed through the world wide IAGIM joint ventures and know-how projects currently active in over 15 countries.

The Handbook is available in electronic format (CD ROM) and the e-format is up-dated annually to IAGIM association members of IAGIM who purchase the e-version and usage license.

This **updated** international edition of the Handbook is copyright protected and is published in photocopy resistant acid proof 80 gram paper has been redesigned and updated to meet the latest technology advancements

Editorial Advisory Board.



ISSN 0793 **8632**

An on-going series

Additional Volumes in Preparation

General Drug Development *Series* ISSN 0973 7601

Electronic Drug Development *Series* ISSN 0973 **761X**



International Edition



© COPYRIGHT PROTECTED

Locum International Press.

